<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	
	>
<channel>
	<title>
	Comments on: Daiichi Sankyo Initiates Clinical Trial with its 4th DXd Antibody Drug Conjugate, DS-7300, in Collaboration with Sarah Cannon Research Institute	</title>
	<atom:link href="https://www.novumpr.nl/2019/10/31/daiichi-sankyo-initiates-clinical-trial-with-its-4th-dxd-antibody-drug-conjugate-ds-7300-in-collaboration-with-sarah-cannon-research-institute/feed/" rel="self" type="application/rss+xml" />
	<link>https://www.novumpr.nl/2019/10/31/daiichi-sankyo-initiates-clinical-trial-with-its-4th-dxd-antibody-drug-conjugate-ds-7300-in-collaboration-with-sarah-cannon-research-institute/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=daiichi-sankyo-initiates-clinical-trial-with-its-4th-dxd-antibody-drug-conjugate-ds-7300-in-collaboration-with-sarah-cannon-research-institute</link>
	<description>NovumPR press releases</description>
	<lastBuildDate>Thu, 31 Oct 2019 13:51:34 +0000</lastBuildDate>
	<sy:updatePeriod>
	hourly	</sy:updatePeriod>
	<sy:updateFrequency>
	1	</sy:updateFrequency>
	<generator>https://wordpress.org/?v=6.8.3</generator>
</channel>
</rss>
